Global variations in pubertal growth spurts in adolescents living with perinatal HIV
- PMID: 37204259
- PMCID: PMC10355801
- DOI: 10.1097/QAD.0000000000003602
Global variations in pubertal growth spurts in adolescents living with perinatal HIV
Abstract
Objective: To describe pubertal growth spurts among adolescents living with perinatally acquired HIV (ALWPHIV) on antiretroviral therapy (ART).
Design: Observational data collected from 1994 to 2015 in the CIPHER global cohort collaboration.
Methods: ALWPHIV who initiated ART age less than 10 years with at least four height measurements age at least 8 years were included. Super Imposition by Translation And Rotation (SITAR) models, with parameters representing timing and intensity of the growth spurt, were used to describe growth, separately by sex. Associations between region, ART regimen, age, height-for-age (HAZ), and BMI-for-age z -scores (BMIz) at ART initiation (baseline) and age 10 years, and SITAR parameters were explored.
Results: Four thousand seven hundred and twenty-three ALWPHIV were included: 51% from East and Southern Africa (excluding Botswana and South Africa), 17% Botswana and South Africa, 6% West and Central Africa, 11% Europe and North America, 11% Asia-Pacific, and 4% Central, South America, and Caribbean. Growth spurts were later and least intense in sub-Saharan regions. In females, older baseline age and lower BMIz at baseline were associated with later and more intense growth spurts; lower HAZ was associated with later growth spurts. In males, older baseline age and lower HAZ were associated with later and less intense growth spurts; however, associations between baseline HAZ and timing varied by age. Lower HAZ and BMIz at 10 years were associated with later and less intense growth spurts in both sexes.
Conclusion: ALWPHIV who started ART at older ages or already stunted were more likely to have delayed pubertal growth spurts. Longer-term follow-up is important to understand the impact of delayed growth.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
M.V.'s work at CIPHER is funded through Unrestricted Educational grants received from ViiV Healthcare and Janssen to the International AIDS Society. A.So's, institution receives research funding from ViiV Healthcare. C.Th. has received grant funding from ViiV Healthcare via the Penta Foundation (to UCL). A.J. reports grants from Abbvie, Bristol Myers Squibb, Gilead, Janssen Pharmaceuticals and ViiV Healthcare through the PENTA Foundation, and from the European and Developing Countries Clinical Trials Partnership, Gilead Sciences, the International AIDS Society, NHS England, Medical Research Council and PENTA Foundation outside the submitted work. All monies were paid to her institution. I.J.C. received grants from the following companies (via her institution) in the past 3 years: ViiV, AbbVie, Gilead.
Figures
References
-
- UNAIDS. UNAIDS 2020 estimates. Geneva: UNAIDS; 2020.
-
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016. - PubMed
-
- Akseer N, Al-Gashm S, Mehta S, Mokdad A, Bhutta ZA. Global and regional trends in the nutritional status of young people: a critical and neglected age group. Ann N Y Acad Sci 2017; 1393:3–20. - PubMed
